Lantus (Insulin Glargine) in Children Under 12: Transitioning to Adult Diabetes Care

Why the Transition From Pediatric to Adult Care Matters for Lantus Users

Children diagnosed with type 1 diabetes before age 12 spend their formative years in a pediatric endocrinology system built around family-centered care and frequent, supported contact. Moving to adult endocrinology changes almost everything: visit frequency drops, the patient is expected to own their own management, and the clinical team has no shared history with the family.

For Lantus specifically, the stakes are concrete. Insulin glargine provides the flat, 24-hour basal coverage that underpins stable fasting glucose, and any disruption to consistent dosing during the transition period can unravel months of glycemic control. A 2018 analysis published in Diabetes Care found that young adults with type 1 diabetes experienced a statistically significant deterioration in HbA1c in the year following transition, with mean HbA1c rising from 8.1% to 8.6% (P<0.01) in centers without structured transition programs [1].

That 0.5% rise is not trivial. Each 1% increase in HbA1c corresponds to a roughly 30% increase in risk for microvascular complications over a decade, based on data from the DCCT/EDIC cohort [2].

What "Transition" Actually Means Clinically

Transition is not a single appointment. The American Diabetes Association (ADA) defines it as a purposeful, planned movement of adolescents and young adults with chronic conditions from child-centered to adult-oriented health care systems [3]. For a child currently under 12, that process should begin around ages 12 to 14 with skills assessment, even though the final handoff typically happens at 18 to 21 years.

During those intervening years, the pediatric team should be documenting the patient's ability to calculate Lantus doses, recognize hypoglycemia, operate their insulin delivery device, and communicate with a pharmacy independently.

The Insulin Glargine-Specific Problem: Puberty Changes Everything

Puberty introduces a surge in growth hormone and IGF-1 that substantially increases insulin resistance. A child who was stable on 0.5 units/kg/day of insulin glargine at age 10 may need 0.8 to 1.2 units/kg/day by Tanner stage 4. A 2020 paper in the Journal of Clinical Endocrinology and Metabolism documented that total daily insulin dose in adolescents with type 1 diabetes peaks at approximately 1.0 to 1.1 units/kg/day during mid-puberty before declining again in late adolescence [4].

If the transition handoff coincides with this peak demand period, the adult endocrinologist receives a patient whose basal requirements are actively shifting. Clear documentation of recent titration history is not optional. It is the baseline the new provider needs on day one.

FDA Approval Status of Lantus in Children Under 12

Lantus (insulin glargine U-100, Sanofi) carries FDA approval for glycemic control in adults with type 1 and type 2 diabetes and in pediatric patients aged 6 years and older with type 1 diabetes [5]. Children under 6 are outside the labeled indication. Between ages 6 and 12, Lantus is on-label, but the key approval trial (Study 4030) enrolled patients aged 6 to 15, meaning the youngest subgroup data is thinner than in older adolescents.

The newer U-300 formulation (Toujeo) is labeled for adults only, so any child approaching transition on Toujeo is switching to an off-label formulation for their age group, a fact the receiving adult provider should document clearly.

What the Label Says About Pediatric Dosing

The FDA-approved prescribing information for Lantus states that in pediatric patients with type 1 diabetes, insulin requirements may be more variable than in adults, and dose adjustments should be made with caution [5]. Starting doses of 0.1 to 0.2 units/kg/day are standard in newly diagnosed children, with upward titration based on fasting self-monitored blood glucose values.

The prescribing information does not specify a pediatric-to-adult transition protocol, which is why clinical society guidelines fill the gap.

ADA and ISPAD Guidelines on Transition Planning

The ADA Standards of Care in Diabetes (2024, Section 14) state that transition planning should begin no later than early adolescence and that youth should demonstrate self-management competency before transfer to adult care [3]. The International Society for Pediatric and Adolescent Diabetes (ISPAD) 2022 Clinical Practice Consensus Guidelines echo this, recommending a structured transition program of at least 12 months duration before the final handoff [6].

Both sets of guidelines identify the same high-risk period: the 6 months before and 12 months after transfer. This is when appointment no-shows spike, prescription lapses occur, and HbA1c rises.

The ISPAD Competency Checklist Relevant to Lantus Use

ISPAD's 2022 guidelines outline a minimum competency set that adolescents should achieve before transition. For basal insulin users, this includes:

• Ability to calculate or verify the prescribed Lantus dose independently
• Knowledge of injection site rotation and lipohypertrophy recognition
• Understanding of sick-day rules, including when to adjust basal insulin
• Ability to recognize, treat, and document nocturnal hypoglycemia
• Independent pharmacy communication, including prior authorization navigation

A patient who cannot yet perform these tasks reliably at age 12 to 14 needs a structured skills-building plan over the next 4 to 6 years, not a crash course at age 17.

What the ADA Says About Structured Programs

The ADA Standards note that "transition preparation, including the provision of transition support and comprehensive care transition, is associated with improved self-management behaviors and, in some studies, improved metabolic outcomes" [3]. Centers with formal young adult clinics (combining pediatric and adult providers for 18- to 25-year-olds) show consistently better HbA1c outcomes than centers relying on abrupt handoffs.

Dosing Continuity: Ensuring the Lantus Dose Transfers Accurately

One underappreciated risk at transition is a simple transcription error. The pediatric record may document Lantus dose in units/kg, while the adult electronic health record uses total daily units. A child weighing 45 kg on 0.7 units/kg/day takes 31.5 units, typically rounded to 32 units. If the adult provider reads "0.7 units/kg" without knowing the current weight, the wrong dose lands in the chart.

The T1D Exchange Quality Improvement Collaborative, which tracks outcomes across 33 U.S. Diabetes centers, reported that insulin dosing errors at care transitions accounted for a disproportionate share of diabetes-related emergency department visits in young adults aged 18 to 25 [7].

Practical Steps to Protect Dosing Accuracy

A direct-communication visit between the outgoing pediatric provider and incoming adult provider reduces errors. Where that is not feasible, a written transition summary should include:

1. Current Lantus dose in total daily units (not units/kg)
2. Most recent titration date and the titration algorithm in use
3. Hypoglycemia frequency over the prior 3 months
4. Current HbA1c with date
5. CGM or SMBG data summary (time-in-range if available)

The receiving adult endocrinologist should treat the first visit as a dose verification appointment, not a dose optimization appointment. Changing the Lantus formulation (e.g., U-100 to U-300) at the same visit as a provider change adds a second variable the patient may not be equipped to manage safely.

Continuous Glucose Monitoring and the Transition Period

CGM technology has meaningfully changed the risk profile of the transition period. A 2021 study in Diabetes Technology and Therapeutics (N=312 young adults) found that patients who used CGM throughout the transition period maintained a mean HbA1c 0.4% lower than those relying on SMBG alone, with no significant difference in hypoglycemia rates [8].

For children under 12 on Lantus who are already using a Dexcom G7 or FreeStyle Libre 3, the CGM data trail provides the adult endocrinologist with objective evidence of basal insulin performance: overnight glucose stability, dawn phenomenon magnitude, and frequency of nocturnal lows.

Interpreting CGM Data to Audit Lantus Performance

The key CGM metrics for basal insulin adequacy are:

• Fasting time-in-range (70 to 180 mg/dL) from 2:00 to 6:00 AM: target above 90%
• Mean fasting glucose on waking: target 80 to 130 mg/dL per ADA pediatric standards
• Coefficient of variation (CV): below 36% suggests adequate glycemic stability

If the overnight trace shows persistent hyperglycemia above 180 mg/dL without a corresponding carbohydrate load, the Lantus dose may be insufficient. A consistent 3:00 AM low followed by fasting hyperglycemia (Somogyi-like pattern) suggests over-baselining. Adult providers inheriting a pediatric CGM user should review at least 14 days of trend data before adjusting Lantus.

Psychosocial Dimensions of Transition

The clinical hand-off is only part of the challenge. Adolescents with type 1 diabetes show higher rates of diabetes distress, depression, and disordered eating than the general population, and these conditions worsen at transition when the support network contracts.

A 2019 systematic review in Pediatric Diabetes (17 studies, N=4,982) found that depressive symptoms were present in approximately 15 to 20% of adolescents with type 1 diabetes approaching the transition period, and that psychosocial screening was documented in fewer than 40% of transition visits [9]. Depression correlates directly with missed insulin doses. For a child on Lantus, skipping a single basal dose raises fasting glucose by roughly 60 to 120 mg/dL overnight and sets up the next day with an insulin deficit that rapid-acting analogs alone may not fully correct.

Building Durable Self-Management Habits Before the Handoff

The HealthRX clinical team uses a three-phase framework for Lantus users under 12 approaching the eventual transition:

Phase 1 (ages 10 to 13): Supervised independence. The child checks their own Lantus pen, confirms the dose out loud, and injects without parental hand-holding, but a parent observes and documents.

Phase 2 (ages 14 to 16): Observed autonomy. The child manages all Lantus-related tasks without prompting. The parent's role shifts to weekly medication review rather than daily oversight. The pediatric team assesses competency formally at each visit using a standardized checklist.

Phase 3 (ages 17 to 18): Transfer readiness. The patient attends at least two appointments without a parent in the room, communicates directly with the pharmacy, and can articulate their sick-day basal protocol to the provider without prompting.

This three-phase model is not validated in a randomized trial. It reflects clinical consensus and the ISPAD competency framework, adapted for practical use.

Insurance, Prior Authorizations, and the Pharmacy Bridge

Adult insurance plans often have different formulary positions for Lantus than pediatric plans. A child covered under a parent's employer plan who ages off at 26 (or off a state Medicaid pediatric program at 18 to 19) may face a prior authorization requirement for Lantus that did not exist before.

Biosimilar insulin glargines (Basaglar, Rezvoglar, Semglee) are interchangeable with Lantus at the FDA level [10], but a formulary switch imposed by a new adult insurer without clinical input is still a dose-interruption risk. The adult provider should document the formulary field at the first visit and, where possible, work with a diabetes care and education specialist (DCES) to preemptively file prior authorizations before the child's existing coverage lapses.

The ADA's Standards of Care explicitly note that "cost is a critical factor in medication access" and that providers should discuss affordable insulin options proactively [3]. Sanofi's Insulins Valyou savings program caps Lantus cost at $99/month for eligible patients without insurance, a specific option worth communicating at the transition visit.

What Adult Endocrinologists Should Know on Day One

Adult endocrinologists who receive patients transitioning from pediatric care under age 12 are inheriting a patient who has lived with type 1 diabetes for most or all of their life. The disease psychology is different from an adult newly diagnosed at age 30. Diabetes is not new information to this patient. The system is.

Key items the adult provider needs at the first visit:

• Total duration of diabetes (years with type 1)
• HbA1c trend over the prior 24 months, not just the most recent value
• Hypoglycemia unawareness status (confirmed or suspected)
• Lantus dose history with titration rationale
• Prior severe hypoglycemic events (loss of consciousness, seizure, glucagon use)
• Current CGM or SMBG regimen with average daily glucose and CV
• Complication screening status (retinopathy, nephropathy, neuropathy)
• Mental health screening results from the pediatric team

A 2022 quality improvement report from the Pediatric Endocrine Society found that fewer than 55% of transition summaries sent to adult providers included all eight of these data categories [11]. The gap is a care quality problem the pediatric team can solve by using a standardized electronic transition summary template.

Special Considerations for the Youngest Patients (Under 6)

Children diagnosed with type 1 diabetes under age 6 present a specific challenge: Lantus is not FDA-labeled for this age group [5]. Many pediatric centers use insulin glargine off-label in children as young as 1 to 2 years, typically at low doses of 0.1 units/kg/day or less, often splitting the dose to reduce nocturnal hypoglycemia risk.

A child diagnosed at age 4 who is now stable on off-label Lantus at age 8 is approaching the labeled indication boundary. The adult provider receiving this patient at age 18 should understand that the child's entire early insulin history was off-label and may have included frequent dose reformulations, pump trials, and unconventional regimens driven by the extreme insulin sensitivity of very young children.

ISPAD's 2022 guidelines specifically address the under-6 population, noting that closed-loop (automated insulin delivery) systems are now preferred over multiple daily injections in this age group when available, but that many families continue with basal-bolus regimens including Lantus due to access or preference [6].

Timing the Transition: When Not to Hand Off

Three clinical situations argue for delaying the transition handoff even if the patient has reached the center's standard age cutoff:

1. Active ketoacidosis or recent severe hypoglycemic episode. Stabilize first. Transfer during a glycemic crisis adds instability.
2. Active psychiatric illness. A patient in an acute depressive episode or eating disorder treatment is not ready to build a new provider relationship simultaneously.
3. Recent Lantus formulation or device change. If the patient just switched from U-100 to U-300 Toujeo or from injections to a smart pen, allow 3 to 6 months to confirm the new regimen is stable before adding a provider change.

The ISPAD guidelines support individualized timing over strict age cutoffs, stating that "the transition should occur when the young person is medically and psychologically ready, not at an arbitrary chronological age" [6].